Hem › Wilms tumör › District of Columbia
Kliniska studier för Wilms tumör i District of Columbia
7 studier för Wilms tumör söker deltagare vid platser i District of Columbia.
Städer i District of Columbia
Officiell studietext (engelska)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Children's National Medical Center, Washington D.C.
RekryterarFas 2
Ålder 12 till 39 · Alla kön · Uppdaterad 29 sep. 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
RekryterarFas 2
Upp till ålder 30 · Alla kön · Uppdaterad 25 aug. 2026 · NCT04322318Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
RekryterarFas 1
Ålder 1 till 23 · Alla kön · Uppdaterad 13 aug. 2026 · NCT07172958Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's National Medical Center, Washington D.C.
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 19 maj 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Children's National Hospital (Data Collection Only), Washington D.C.
RekryterarFas 2
12 Months · Alla kön · Uppdaterad 6 maj 2026 · NCT05985161A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's National Medical Center, Washington D.C.
RekryterarFas 2
18 Months – 40 Years · Alla kön · Uppdaterad 12 aug. 2025 · NCT05135975Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.